Celldex Therapeutics Inc (CLDX) - Total Assets
Based on the latest financial reports, Celldex Therapeutics Inc (CLDX) holds total assets worth $511.25 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Celldex Therapeutics Inc - Total Assets Trend (1985–2025)
This chart illustrates how Celldex Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. Also see Celldex Therapeutics Inc market cap and net worth for the company's overall valuation and market capitalisation.
Celldex Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Celldex Therapeutics Inc's total assets of $511.25 Million consist of 91.7% current assets and 8.3% non-current assets. Review CLDX total liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 5.0% |
| Accounts Receivable | $2.02 Million | 0.4% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $27.19 Million | 4.7% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1985–2025)
This chart illustrates how Celldex Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Celldex Therapeutics Inc (CLDX) stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Celldex Therapeutics Inc's current assets represent 91.7% of total assets in 2025, an increase from 87.5% in 1985.
- Cash Position: Cash and equivalents constituted 5.0% of total assets in 2025, down from 75.0% in 1985.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 0.0% in 1985.
- Asset Diversification: The largest asset category is intangible assets at 4.7% of total assets.
Celldex Therapeutics Inc Competitors by Total Assets
Key competitors of Celldex Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Celldex Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.92 | 21.67 | 11.57 |
| Quick Ratio | 8.92 | 21.67 | 11.57 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $407.75 Million | $661.74 Million | $153.12 Million |
Celldex Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Celldex Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.60 |
| Latest Market Cap to Assets Ratio | 5.18 |
| Asset Growth Rate (YoY) | -26.4% |
| Total Assets | $582.98 Million |
| Market Capitalization | $3.02 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Celldex Therapeutics Inc's assets at a significant premium (5.18x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Celldex Therapeutics Inc's assets decreased by 26.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Celldex Therapeutics Inc (1985–2025)
The table below shows the annual total assets of Celldex Therapeutics Inc from 1985 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $582.98 Million | -26.42% |
| 2024-12-31 | $792.34 Million | +70.17% |
| 2023-12-31 | $465.63 Million | +32.00% |
| 2022-12-31 | $352.74 Million | -20.67% |
| 2021-12-31 | $444.65 Million | +88.54% |
| 2020-12-31 | $235.84 Million | +91.84% |
| 2019-12-31 | $122.93 Million | -21.10% |
| 2018-12-31 | $155.81 Million | -50.63% |
| 2017-12-31 | $315.62 Million | -17.67% |
| 2016-12-31 | $383.36 Million | +13.56% |
| 2015-12-31 | $337.58 Million | +36.11% |
| 2014-12-31 | $248.01 Million | -28.55% |
| 2013-12-31 | $347.10 Million | +176.48% |
| 2012-12-31 | $125.54 Million | +28.11% |
| 2011-12-31 | $97.99 Million | -10.87% |
| 2010-12-31 | $109.94 Million | -21.67% |
| 2009-12-31 | $140.36 Million | +101.11% |
| 2008-12-31 | $69.79 Million | +85.38% |
| 2007-12-31 | $37.65 Million | -38.76% |
| 2006-12-31 | $61.48 Million | +68.66% |
| 2005-12-31 | $36.45 Million | -20.42% |
| 2004-12-31 | $45.80 Million | +46.31% |
| 2003-12-31 | $31.31 Million | -11.15% |
| 2002-12-31 | $35.23 Million | -34.12% |
| 2001-12-31 | $53.48 Million | -15.86% |
| 2000-12-31 | $63.56 Million | +219.69% |
| 1999-12-31 | $19.88 Million | -12.41% |
| 1998-12-31 | $22.70 Million | +131.63% |
| 1997-12-31 | $9.80 Million | -43.02% |
| 1996-12-31 | $17.20 Million | -7.03% |
| 1995-12-31 | $18.50 Million | -10.63% |
| 1994-12-31 | $20.70 Million | -37.46% |
| 1993-12-31 | $33.10 Million | +47.77% |
| 1992-12-31 | $22.40 Million | +69.70% |
| 1991-12-31 | $13.20 Million | 0.00% |
| 1990-12-31 | $13.20 Million | -15.38% |
| 1989-12-31 | $15.60 Million | +18.18% |
| 1988-12-31 | $13.20 Million | +1.54% |
| 1987-12-31 | $13.00 Million | -10.96% |
| 1986-12-31 | $14.60 Million | +356.25% |
| 1985-12-31 | $3.20 Million | -- |
About Celldex Therapeutics Inc
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzo… Read more